Tianjin cancer hospital airport hospital (Tianjin, China), China
Mengrong Li is a dedicated Pharmacist at Tianjin Cancer Hospital Airport Hospital in China, holding a Master’s degree in Pharmaceutical Analysis from Tianjin University of Traditional Chinese Medicine. With over six years of research experience, her work lies at the intersection of analytical pharmacology and clinical oncology. She specializes in drug metabolism, blood drug concentration analysis, and the development of quality standards for pharmaceutical preparations. Having published five SCI-indexed journal articles and contributed to ten patents (seven granted, three pending), her contributions reflect a strong commitment to innovation in therapeutic drug monitoring. Mengrong has also participated in major national research collaborations, including a Beijing Municipal “Epidemic Prevention and Control” project and studies funded by the National Natural Science Foundation of China. Her work not only enhances personalized treatment strategies for cancer patients but also elevates the national drug standardization framework. She is emerging as a promising researcher in cancer pharmacology.
Profile
Orcid
🎓 Education
Mengrong Li completed her Master’s degree in Pharmaceutical Analysis at Tianjin University of Traditional Chinese Medicine, where she specialized in drug metabolism, pharmacokinetics, and quality control techniques. Her academic foundation combines both traditional and modern pharmaceutical sciences, with a focus on bridging clinical application and analytical research. Professionally, she has worked for six years in a clinical research setting at Tianjin Cancer Hospital Airport Hospital, where she currently serves as a Pharmacist. Her responsibilities include developing blood concentration detection methods and interpreting data to predict therapeutic efficacy and adverse reactions. As a principal investigator, she has led formulation research under government-funded epidemic control projects and taken part in key collaborations funded by the National Natural Science Foundation of China. Her profile reflects a blend of hands-on pharmaceutical practice and deep research insight, making her a significant contributor to China’s efforts in cancer therapy and drug quality assurance.
💼 Experience
Currently working as a Pharmacist at Tianjin Cancer Hospital Airport Hospital, Mengrong Li has accumulated six years of interdisciplinary experience in pharmaceutical research and clinical application. Her core responsibilities involve the development and validation of drug concentration assays used to monitor patient responses and optimize dosage in cancer treatments. She has also played a significant role in the formulation and quality control of traditional medicine preparations, two of which were recognized as Chinese national standards. Mengrong has completed one major project and is currently involved in two ongoing research studies, including collaborations under the National Natural Science Foundation and the Beijing Science and Technology Commission. Her patent contributions and publications underscore her ability to translate laboratory innovations into practical tools for clinical practice. Additionally, her mentorship of students reflects her dedication to nurturing the next generation of researchers. Her holistic experience covers research, clinical diagnostics, product development, and regulatory compliance.
🏆 Awards and Honors
Mengrong Li has made impactful contributions to cancer pharmacology and pharmaceutical analysis, earning recognition through multiple patents and peer-reviewed publications. Among her most notable achievements are ten patents (seven granted and three pending), many of which stemmed from her original research in drug quality control and therapeutic drug monitoring. She has published five SCI-indexed articles and received a total of 80 citations, with an h-index of 3. Her research work contributed to the national standardization of two formula particle preparations for traditional medicine, showcasing her influence in policy-level pharmaceutical development. She has participated as the principal investigator in projects funded by major scientific bodies such as the Beijing Municipal Science & Technology Commission and the National Natural Science Foundation of China. These achievements, along with her active involvement in three major research projects and student mentorship, reflect a deep and consistent record of excellence and innovation in healthcare and science.
🔬 Research Focus
Mengrong Li’s research centers on analytical method development for drug quality control and therapeutic drug monitoring, with a special emphasis on cancer pharmacology. Her work bridges laboratory and clinical settings, aiming to ensure optimal medication dosing and minimize adverse effects in oncology patients. She has developed blood drug concentration detection protocols and studied their correlation with therapeutic outcomes. A key focus of her research has been on the pharmacokinetics of traditional Chinese medicines and modern chemotherapeutic agents. Mengrong’s research has led to the establishment of two national pharmaceutical standards and contributed to the formulation of institutional drugs during public health emergencies. Her contributions also include eight patent applications and the publication of SCI-indexed papers addressing cancer drug metabolism and dose optimization. By integrating analytical pharmacology and clinical needs, her work supports the personalization of cancer treatment, aligning with global trends toward precision medicine.
✅ Conclusion
Mengrong Li is a highly promising candidate for the Best Researcher Award. Her integrated approach to pharmaceutical analysis and cancer pharmacology, backed by patents and policy-level contributions, underscores her potential as a translational researcher. With expanded international engagement and academic leadership, she is well-positioned to become a key innovator in precision medicine and pharmacological research.
Publication
Title: In-syringe polypropylene fiber-supported liquid-phase microextraction followed by LC-MS/MS for rapid and sensitive determination of tyrosine kinase inhibitors in plasma
Year: 2025
Authors: Dong Wang, Mengrong Li, Tingting Dai, Xiangyu Zhang, Di Chen
Link: https://doi.org/10.1016/j.microc.2025.114222
Title: Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation
Year: 2025
Authors: Lili Su, Xiangyu Zhang, Mengrong Li, Ying Li, Dong Wang
Link: https://doi.org/10.1080/14737167.2025.2518135
Title: Integration of multicomponent characterization, untargeted metabolomics and mass spectrometry imaging to unveil the holistic chemical transformations and key markers associated with wine steaming of Ligustri Lucidi Fructus
Year: 2020
Authors: Mengrong Li, Xiaoyan Wang, Lifeng Han, Li Jia, Erwei Liu, Zheng Li, Heshui Yu, Yucheng Wang, Xiumei Gao, Wenzhi Yang
Link: https://doi.org/10.1016/j.chroma.2020.461228
Title: Identification of prototypes from Ligustri Lucidi Fructus in rat plasma based on a data‐dependent acquisition and multicomponent pharmacokinetic study
Year: 2020
Authors: Yucheng Wang, Keyu Feng, Mengrong Li, Lifeng Han, Weiqiang Wang, Dandan Si, Xiaopeng Chen, Wenzhi Yang, Xiumei Gao, Erwei Liu
Link: https://doi.org/10.1002/bmc.4833
Title: Enhanced identification of the in vivo metabolites of Ecliptae Herba in rat plasma by integrating untargeted data-dependent MS2 and predictive multiple reaction monitoring-information dependent acquisition-enhanced product ion scan
Year: 2019
Authors: Mengrong Li, Dandan Si, Zhifei Fu, Mangmang Sang, Zixin Zhang, Erwei Liu, Wenzhi Yang, Xiumei Gao, Lifeng Han
Link: https://doi.org/10.1016/j.jchromb.2019.02.001